Zepzelca and Tecentriq Show Promising Survival Benefits in Extensive-Stage SCLC

The IMforte trial results have highlighted the promising survival benefits of combining Zepzelca with Tecentriq for patients with extensive-stage small cell lung cancer (ES-SCLC). Conducted by Jazz Pharmaceuticals, the Phase III study demonstrated significant improvements in both overall and progression-free survival when Zepzelca was used as a first-line maintenance therapy alongside Tecentriq, compared to Tecentriq alone[1][2]. The treatment regimen was well-received, showing familiar toxicities without new safety issues, paving the way for Jazz to file a supplemental New Drug Application in 2025[1].